Pomerantz Law Firm Files Class Action Lawsuit Against Aardvark Therapeutics

Pomerantz LLP announced the filing of a class action lawsuit against Aardvark Therapeutics, Inc. and certain of its officers and directors. The suit, filed in the U.S. District Court for the Southern District of California, alleges that documents related to the company's initial public offering (IPO) and securities traded between February 13, 2025, and May 14, 2026, contained misrepresentations and omissions.

The complaint claims that Aardvark and its management made materially false and misleading statements regarding the company's business, operations, and prospects. Specifically, the suit alleges that the safety, clinical, regulatory, and commercial prospects of its lead drug candidate, ARD-101, were overstated. Concerns began to surface on February 27, 2026, when Aardvark announced it was voluntarily pausing a clinical trial.

Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies to inhibit hunger and treat metabolic diseases. Its lead candidate, ARD-101, is designed to target bitter taste receptors (TAS2Rs) expressed in the gut, aiming to reduce hyperphagia.

Investors who purchased Aardvark common stock pursuant to the offering documents or during the class period have until October 13, 2026, to seek appointment as lead plaintiff. The lawsuit pursues claims under the Securities Act of 1933 and the Securities Exchange Act of 1934.